ProCE Banner Activity

Immune Checkpoint Inhibitor–Based Therapy for Early-Stage Lung Cancer: Medical Oncology Perspective

Slideset Download

Download this slideset to review key data on the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for resectable early-stage NSCLC.

Released: August 26, 2021

Share

Faculty

Patrick Forde

Patrick Forde, MBBCh

Director, Thoracic Oncology Research Program
Oncology Department
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Patrick Forde, MBBCh

Director, Thoracic Oncology Research Program
Oncology Department
Johns Hopkins University
Baltimore, Maryland

Patrick Forde, MBBCh: consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Daichii Sankyo, F Star, Genentech, Gritstone, G1 Therapeutics, Iteos, Janssen, Novartis, Regeneron, Sanofi, Surface; researcher (paid to institution): AstraZeneca, Biontech, Bristol-Myers Squibb, Regeneron.